Immunotherapy can now be regarded as an attractive approach for cancer and infectious disease treatments [...].
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC10819851 | PMC |
| http://dx.doi.org/10.3390/vaccines12010042 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Plasma anti-CD4 IgG levels are associated with poor immune recovery in people with HIV initiating antiretroviral therapy.
AIDS
February 2025
Division of Infectious Diseases, Department of Medicine, Weill Cornell Medicine, New York, NY.
A segment of people with HIV on effective antiretroviral therapy (ART) continue to experience poor immune recovery, leaving them at heightened risk of non-AIDS-defining events (NAEs). The production of anti-CD4 IgG autoreactive antibodies is suggested as one contributing mechanism to these complications. Here, we found that plasma anti-CD4 levels do not discriminate immunological responders from nonresponders nor predict the occurrence of NAEs, suggesting it is unlikely a contributing immunopathological factor associated with these complications.
View Article and Find Full Text PDFSulfites: The 2024 American Contact Dermatitis Society Allergen of the Year.
Cutis
November 2024
Solbie Choi is from the Albert Einstein College of Medicine, Bronx, New York. Sarak K. Zemlok is from the University of Connecticut School of Medicine, Farmington. Dr. Yu is from the Department of Dermatology, Massachusetts General Hospital, Harvard Medical School, Boston. Dr. Adler is from the Department of Dermatology, Keck School of Medicine, University of Southern California, Los Angeles.
The American Contact Dermatitis Society (ACDS) selected sulfites as the 2024 Allergen of the Year. These common and potentially allergenic ingredients are used as preservatives and antioxidants in a variety of foods, beverages, medications, and personal care products. In this article, we review common sources of sulfite exposure, clinical manifestations of allergic contact dermatitis (ACD) to sulfites, and patch testing considerations for this emerging allergen.
View Article and Find Full Text PDFLFA-1: A potential key player in microglia-mediated neuroprotection against oxygen-glucose deprivation in vitro.
PLoS One
January 2025
Medical Faculty, Department of Neurology, Otto von Guericke University, Magdeburg, Germany.
For the last 38 years, all neuroprotective agents for patients with ischemic stroke have failed in clinical trials. The innate immune system, particularly microglia, is a much-discussed target for neuroprotective agents. Promising results for neuroprotection by inhibition of integrins with drugs such as natalizumab in animal stroke models have not been translated into clinical practice.
View Article and Find Full Text PDFA signaling molecule from intratumor bacteria promotes trastuzumab resistance in breast cancer cells.
Proc Natl Acad Sci U S A
January 2025
Key Laboratory of Molecular Nanostructure and Nanotechnology, Research/Education Center for Excellence in Molecular Sciences, Institute of Chemistry, Chinese Academy of Sciences, Beijing 100190, China.
Emerging evidence indicates that intratumor bacteria exist as an active and specific tumor component in many tumor types beyond digestive and respiratory tumors. However, the biological impact and responsible molecules of such local bacteria-tumor direct interaction on cancer therapeutic response remain poorly understood. Trastuzumab is among the most commonly used drugs targeting the receptor tyrosine-protein kinase erbB-2 (ErbB2) in breast cancer, but its resistance is inevitable, severely limiting its clinical effectiveness.
View Article and Find Full Text PDFAnti-CTLA-4 generates greater memory response than anti-PD-1 via TCF-1.
Proc Natl Acad Sci U S A
January 2025
Department of Immunology, The University of Texas MD Anderson Cancer Center, Houston, TX 77030.
The effects of T cell differentiation arising from immune checkpoint inhibition targeting cytotoxic T lymphocyte-associated antigen 4 (CTLA-4) and programmed cell death protein 1 (PD-1) on the immunological memory response remain unclear. Our investigation into the effects of anti-CTLA-4 and anti-PD-1 on memory T cell formation in mice reveals that memory T cells generated by anti-CTLA-4 exhibit greater expansion, cytokine production, and antitumor activity than those from anti-PD-1. Notably, anti-CTLA-4 preserves more T cell factor-1 (TCF-1)+ T cells during priming, while anti-PD-1 leads to more thymocyte selection-associated high mobility group box (TOX)+ T cells.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!